Kin Health | $9,000,000 | (May 20, 2026)
Scope AI | $20,000,000 | (May 20, 2026)
Leadbay (YC F25) | $4,300,000 | (May 20, 2026)
Certified by Founder
Lodge
Ankyra Therapeutics
start up
United States
- Boston, Massachusetts
- 12/11/2021
- Series B
- $45,000,000
Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
- Industry Biotechnology Research
- Website https://ankyratx.com/
- LinkedIn https://www.linkedin.com/company/ankyratx/about/
Related People
Howard KaufmanFounder
United States -
Boston, Massachusetts
Experienced Chief Medical Officer with a demonstrated history of working in academic medicine and the biotechnology industry. Skilled in Cancer Research, Biotechnology, Healthcare Management, Healthcare, and Life Sciences. Strong healthcare services professional with considerable expertise in cancer immunotherapy and drug development.
Hellbender Inc. | $12,500,000 | (May 20, 2026)
Rely | $4,500,000 | (May 20, 2026)
bunch | $35,000,000 | (May 20, 2026)
Vital Signals | $15,000,000 | (May 20, 2026)
viktor.com | $75,000,000 | (May 20, 2026)
Brami Inc. | $33,000,000 | (May 20, 2026)
Benji | $6,250,000 | (May 20, 2026)
Blank Bio | $7,200,000 | (May 20, 2026)
Hacktron AI | $2,900,000 | (May 19, 2026)